Literature DB >> 23015677

Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women.

Romy van Baars1, Remko P Bosgraaf, Bram W A ter Harmsel, Willem J G Melchers, Wim G V Quint, Ruud L M Bekkers.   

Abstract

Primary screening using high-risk human papillomavirus (hrHPV) detection has been suggested as a way of improving cervical cancer prevention. Women currently not attending screening (nonresponders) are more likely to participate when given the opportunity of self-sampling for hrHPV testing. The Evalyn Brush is a new cervicovaginal self-sampling device, developed specifically to meet women's demands, which is user-friendly and easy to use. The aims of this study were to investigate agreement of hrHPV detection by two PCR methods between the Evalyn Brush and physician-obtained samples and to study women's acceptance of this self-sampling device. Each of 134 women visiting the gynecology outpatient clinic collected a self-obtained sample (self-sample) and completed a questionnaire. The brush was stored dry. After self-sampling, a trained physician obtained a conventional cervical cytology specimen in ThinPrep medium. HrHPV detection was performed using the SPF(10)-DEIA-LiPA(25) and GP5+/6+-LQ-test. The overall agreement for hrHPV detection using SPF(10)-DEIA-LiPA(25) between the self-sample and the physician-taken sample was 85.8% (kappa value, 0.715; 95% confidence interval [CI], 0.597 to 0.843; P = 1.000). The overall agreement for hrHPV detection using GP5+/6+-LQ between the self-sample and the physician-taken sample was 86.6% (kappa value, 0.725; 95% CI, 0.607 to 0.843; P = 0.815). Ninety-eight percent of the women rated their experience as good to excellent. Moreover, 95% of women preferred self-sampling to physician sampling. Self-sampling using the dry Evalyn Brush system is as good as a physician-taken sample for hrHPV detection and is highly acceptable to women. To validate this self-sampling device for clinical use, a large screening cohort should be studied.

Entities:  

Mesh:

Year:  2012        PMID: 23015677      PMCID: PMC3503012          DOI: 10.1128/JCM.01506-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  51 in total

1.  POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.

Authors:  Nicole W J Bulkmans; Lawrence Rozendaal; Peter J F Snijders; Feja J Voorhorst; A Joan P Boeke; Gladys R J Zandwijken; Folkert J van Kemenade; René H M Verheijen; Krijn v Groningen; Mathilde E Boon; Hans J F Keuning; Marjolein van Ballegooijen; Adriaan J C van den Brule; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-05-20       Impact factor: 7.396

2.  HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.

Authors:  T C Wright; L Denny; L Kuhn; A Pollack; A Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  Screening for cervical neoplasia by self-assessment for human papillomavirus DNA.

Authors:  P Hillemanns; R Kimmig; U Hüttemann; C Dannecker; C J Thaler
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

4.  Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up.

Authors:  W J Melchers; J M Bakkers; J Wang; P C de Wilde; H Boonstra; W G Quint; A G Hanselaar
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

5.  Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction.

Authors:  P E Gravitt; J V Lacey; L A Brinton; W A Barnes; J R Kornegay; M D Greenberg; S M Greene; O C Hadjimichael; L McGowan; R Mortel; P E Schwartz; R Zaino; A Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-02       Impact factor: 4.254

6.  Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.

Authors:  J W Sellors; A T Lorincz; J B Mahony; I Mielzynska; A Lytwyn; P Roth; M Howard; S Chong; D Daya; W Chapman; M Chernesky
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

7.  Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia.

Authors:  J Belinson; Y L Qiao; R Pretorius; W H Zhang; P Elson; L Li; Q J Pan; C Fischer; A Lorincz; D Zahniser
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

8.  Tampons: a novel patient-administered method for the assessment of genital human papillomavirus infection.

Authors:  C K Fairley; S Chen; S N Tabrizi; M A Quinn; J J McNeil; S M Garland
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

9.  Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.

Authors:  Fang-Hui Zhao; Adam K Lewkowitz; Feng Chen; Margaret J Lin; Shang-Ying Hu; Xun Zhang; Qin-Jing Pan; Jun-Fei Ma; Mayineur Niyazi; Chang-Qing Li; Shu-Min Li; Jennifer S Smith; Jerome L Belinson; You-Lin Qiao; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2012-01-23       Impact factor: 13.506

10.  Attitudes to self-sampling for HPV among Indian, Pakistani, African-Caribbean and white British women in Manchester, UK.

Authors:  S Forrest; K McCaffery; J Waller; M Desai; A Szarewski; L Cadman; J Wardle
Journal:  J Med Screen       Date:  2004       Impact factor: 2.136

View more
  21 in total

1.  Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States.

Authors:  Jennifer S Smith; Andrea C Des Marais; Allison M Deal; Alice R Richman; Carolina Perez-Heydrich; Belinda Yen-Lieberman; Lynn Barclay; Jerome Belinson; Allen Rinas; Noel T Brewer
Journal:  Sex Transm Dis       Date:  2018-01       Impact factor: 2.830

2.  Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.

Authors:  Lise M A De Strooper; Viola M J Verhoef; Johannes Berkhof; Albertus T Hesselink; Helena M E de Bruin; Folkert J van Kemenade; Remko P Bosgraaf; Ruud L M Bekkers; Leon F A G Massuger; Willem J G Melchers; Renske D M Steenbergen; Peter J F Snijders; Chris J L M Meijer; Daniëlle A M Heideman
Journal:  Gynecol Oncol       Date:  2016-03-03       Impact factor: 5.482

3.  Evaluation of the Impact of Human Papillomavirus DNA Self-sampling on the Uptake of Cervical Cancer Screening.

Authors:  Eliza L Y Wong; Paul K S Chan; Josette S Y Chor; Annie W L Cheung; Fenwei Huang; Samuel Y S Wong
Journal:  Cancer Nurs       Date:  2016 Jan-Feb       Impact factor: 2.592

4.  Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program.

Authors:  Mette Tranberg; Bodil Hammer Bech; Jan Blaakær; Jørgen Skov Jensen; Hans Svanholm; Berit Andersen
Journal:  BMC Cancer       Date:  2016-11-03       Impact factor: 4.430

5.  Qualitative study of barriers to cervical cancer screening among Nigerian women.

Authors:  Fatima Isa Modibbo; Eileen Dareng; Patience Bamisaye; Elima Jedy-Agba; Ayodele Adewole; Lawal Oyeneyin; Olayinka Olaniyan; Clement Adebamowo
Journal:  BMJ Open       Date:  2016-01-11       Impact factor: 2.692

Review 6.  Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer.

Authors:  Xaveer Van Ostade; Martin Dom; Wiebren Tjalma; Geert Van Raemdonck
Journal:  Arch Gynecol Obstet       Date:  2017-11-15       Impact factor: 2.344

7.  Self-sampling for human papillomavirus DNA detection: a preliminary study of compliance and feasibility in BOLIVIA.

Authors:  Pedro Surriabre; Gustavo Allende; Marcela Prado; Leyddy Cáceres; Diego Bellot; Andrea Torrico; Karina Ustariz; Shirley Rojas; Jaime Barriga; Pamela Calle; Ligia Villarroel; Rosse Mary Yañez; Marc Baay; Patricia Rodriguez; Véronique Fontaine
Journal:  BMC Womens Health       Date:  2017-12-22       Impact factor: 2.809

8.  Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria.

Authors:  Fatima Modibbo; K C Iregbu; James Okuma; Annemiek Leeman; Annemieke Kasius; Maurits de Koning; Wim Quint; Clement Adebamowo
Journal:  Infect Agent Cancer       Date:  2017-02-06       Impact factor: 2.965

9.  DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women.

Authors:  A Boers; R P Bosgraaf; R W van Leeuwen; E Schuuring; D A M Heideman; L F A G Massuger; V M J Verhoef; J Bulten; W J G Melchers; A G J van der Zee; R L M Bekkers; G B A Wisman
Journal:  Br J Cancer       Date:  2014-07-17       Impact factor: 7.640

10.  Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial.

Authors:  K Haguenoer; S Sengchanh; C Gaudy-Graffin; J Boyard; R Fontenay; H Marret; A Goudeau; N Pigneaux de Laroche; E Rusch; B Giraudeau
Journal:  Br J Cancer       Date:  2014-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.